AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 517586
Drug: 2,000 U
RxNorm normalized name: AHF 2,000 UNIT/VWF 800 UNIT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,000 U heparin/12 hr subcutaneously
Trial: 517586
Drug: 5,000 U
RxNorm normalized name: Decara 25,000 UNT Vegicaps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 U heparin/12 hr subcutaneously
Trial: 16507190
Drug: 0.015 mg
RxNorm normalized name: sulfur 0.015 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015 mg morphine (Group I, n=25)
Trial: 16507190
Drug: 0.03 mg
RxNorm normalized name: biotin 0.03 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg morphine (Group II, n=30)
Trial: 16507190
Drug: 0.06 mg
RxNorm normalized name: urea 0.06 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06 mg morphine (Group III, n=31)
Trial: 16507190
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg morphine (Group IV, n=33)
Trial: 16507190
Drug: All morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All morphine groups
Trial: 2902264
Drug: Edmonston-Zagreb (EZ)
RxNorm normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) / varicella-zoster virus vaccine live (Oka-Merck) strain Injection [ProQuad]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edmonston-Zagreb (EZ) measles vaccine, 40,000 PFU at 4 months of age
Trial: 2902264
Drug: Schwarz measles
RxNorm normalized name: measles virus vaccine live, attenuated Schwarz strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schwarz measles vaccine, 6000 TCID50 at 9 months of age
Trial: 2902264
Drug: EZ vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZ vaccine
Trial: 23447519
Drug: Cholic acid
RxNorm normalized name: Cholic Acid
DrugBank: Cholic Acid (DB02659)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cholic acid (CA) 15 mg/kg per day
Trial: 21374656
Drug: PEG‐IFN/ribavirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN/ribavirin therapy
Trial: 11103114
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg of urapidil (group U, n = 22)
Trial: 11103114
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg of urapidil (group U)
Trial: 9179227
Drug: Therapeutic doses
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic doses of 90Y-DOTA-peptide-ChL6
Trial: 9179227
Drug: Tracer doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tracer doses of 111In-DOTA-peptide-ChL6
Trial: 1489548
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of paroxetine, a serotonin re-uptake inhibitor
Trial: 2857117
Drug: Nizatidine 6.25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 6.25, 25, 75, 150, or 250 mg (single 20-min intravenous infusion)
Trial: 2857117
Drug: Nizatidine 25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nizatidine 25, 50, 100, or 250 mg (5-min intravenous infusion weekly for 6 weeks)
Trial: 2857117
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg (5-min intravenous infusion weekly for 6 weeks)
Trial: 2857117
Drug: Placebo (5-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5-min intravenous infusion weekly for 6 weeks)
Trial: 21977812
Drug: Zaizhang Shengxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zaizhang Shengxue Tablet
Trial: 11309012
Drug: B‐IINB (ilioinguinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B‐IINB (ilioinguinal and iliohypogastric nerve block) with 10 ml of 0.5% bupivacaine
Trial: 359083
Drug: Oral neomycin
RxNorm normalized name: neomycin Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral neomycin and metronidazole added to bowel preparation
Trial: 359083
Drug: Standard mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard mechanical preparation
Trial: 28557585
Drug: IMRT and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMRT and concurrent 5-FU/MMC
Trial: 19586142
Drug: Therapeutic alliance
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic alliance intervention (TA) added to usual treatment
Trial: 19586142
Drug: 2‐session, counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2‐session, counseling and education, HIV/HCV risk reduction intervention (C&E) added to usual treatment
Trial: 17542057
Drug: Standard 30-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 30-min infusion of gemcitabine (1200 mg/m(2))
Trial: 17542057
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose rate (FDR) infusion of gemcitabine (10 mg/(m(2) x min))
Trial: 15482353
Drug: Sumatriptan 100
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 100 mg tablets (early treatment)
Trial: 15482353
Drug: Sumatriptan 100
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 100 mg tablets (late treatment)
Trial: 9691162
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (n = 12)
Trial: 3360972
Drug: Metronidazole (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (250 mg three times daily)
Trial: 3360972
Drug: Alprazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (1 mg orally)
Trial: 3360972
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg IV)
Trial: 28103915
Drug: Community health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community health volunteers (CHVs) providing health education, oral rehydration solutions, and zinc tablets for diarrhea, and diagnosing malaria.
Trial: 26581144
Drug: VAC (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC (vincristine, dactinomycin, cyclophosphamide) or VAC alternating with VTC (topotecan) for 42 weeks, with local therapy of 50.4 Gy radiation therapy with or without delayed primary excision starting at week 12 for group III patients.
Trial: 26581144
Drug: Local therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapy with 36-41.4 Gy radiation therapy for group I/II alveolar RMS patients.
Trial: 21338720
Drug: Topical phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical phenytoin dressing once daily
Trial: 9217619
Drug: 10-minute office-staff
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-minute office-staff administered screen for malnutrition/weight loss, visual impairment, hearing loss, cognitive impairment, urinary incontinence, depression, physical limitations, and reduced leg mobility.
Trial: 9217619
Drug: 10-minute office-staff
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-minute office-staff administered screen
Trial: 3542916
Drug: Standard schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard schedule (5 fractions per week of 180 to 200 cGy per day, total dose of 6600‐7380 cGy)
Trial: 24715213
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) followed by D2 gastrectomy
Trial: 23429740
Drug: NUCAI (nurse-led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUCAI (nurse-led psychosocial intervention), consisting of six bimonthly 45-minute counseling sessions, aimed at managing physical, psychological, and social consequences of HNC and its treatment.
Trial: 1464343
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 1 mg
Trial: 1464343
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 2 mg
Trial: 1464343
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate 3 mg
Trial: 378005
Drug: Intravenous cefamandole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cefamandole
Trial: 28940962
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow therapy at 15 L/min
Trial: 28940962
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow therapy at 30 L/min
Trial: 28940962
Drug: Nasal high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high flow therapy at 45 L/min
Trial: 27221555
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPI) long-term therapy
Trial: 17993008
Drug: Shenwu gelatin
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenwu gelatin capsule (5 capsules, 3 times a day for 3 months)
Trial: 17993008
Drug: Aniracetam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aniracetam (2 capsules) with 3 placebo capsules (3 times a day for 3 months)
Trial: 10413761
Drug: HCC (heparin-coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCC (heparin-coated circuits)
Trial: 7675881
Drug: Complete caffeine
RxNorm normalized name: ACETAMINOPHEN 500 mg / PAMABROM 25 mg / PYRILAMINE MALEATE 15 mg ORAL TABLET [Midol Complete Caffeine Free]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete caffeine deprivation (100% of daily caffeine intake)
Trial: 7675881
Drug: Partial caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Partial caffeine deprivation (50% of daily caffeine intake)
Trial: 7675881
Drug: No caffeine
RxNorm normalized name: caffeine Oral Tablet [No Doz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No caffeine deprivation (0% of daily caffeine intake)
Trial: 6110953
Drug: 3 years
RxNorm normalized name: NanoVM 1-3 years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 years of maintenance treatment
Trial: 6110953
Drug: 5 years
RxNorm normalized name: Dymadon 5 Years Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 years of maintenance treatment
Trial: 29872264
Drug: levodropropizine CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodropropizine CR 90 mg two times in the fed state (TF)
Trial: 29872264
Drug: levodropropizine CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodropropizine CR 90 mg two times in the fasted state (T)
Trial: 29872264
Drug: levodropropizine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodropropizine IR 60 mg three times in the fasted state (R)
Trial: 21818642
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g ginger
Trial: 21818642
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g ginger
Trial: 21818642
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g ginger
Trial: 2649632
Drug: Propranolol at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol at 80 mg
Trial: 2649632
Drug: Atenolol at
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol at 50 mg
Trial: 2649632
Drug: Metoprolol at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol at 100 mg
Trial: 2649632
Drug: Renal clearance
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal clearance and urinary excretion
Trial: 26200405
Drug: levobupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine + tramadol 50 mg
Trial: 26200405
Drug: levobupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine + fentanyl 150 mcg
Trial: 26200405
Drug: levobupivacaine 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 2.5 mg/ml
Trial: 3175579
Drug: Metronidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1 g suppositories)
Trial: 3175579
Drug: Ornidazole (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole (500 mg iv or 500 mg suppositories)
Trial: 19422357
Drug: Acid+capsaicin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid+capsaicin (200 ml solution: 180 ml HCL 0.1 M and 2 mg capsaicin in 20 ml solvent)
Trial: 17066105
Drug: 25 G
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 G spinal needle
Trial: 1836989
Drug: 26 G
RxNorm normalized name: Sunmark Lancet Thin 26 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26 G spinal needle
Trial: 12577392
Drug: Shenmai injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenmai injection (SMI) plus thrombolytic treatment
Trial: 12577392
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment only (Control)
Trial: 9435936
Drug: Ciprofloxacin (CF)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CF) 500 mg orally twice daily
Trial: 9435936
Drug: Ceftazidime (CT)
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime (CT) 1 g intravenously twice daily
Trial: 27012781
Drug: Crushed prasugrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed prasugrel 60-mg loading dose
Trial: 22699288
Drug: 0.5 units/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 units/kg/day insulin glargine and glulisine
Trial: 22699288
Drug: 0.25 units/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 units/kg/day insulin glargine and glulisine
Trial: 22699288
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing groups (0.5 and 0.25 units/kg/day)
Trial: 16255837
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (clobetasol propionate 0.05%, betamethasone valerate 0.1%, clobetasone butyrate 0.05%)
Trial: 14733854
Drug: Consulting of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consulting of internal medicine (CIM) in primary care
Trial: 3168936
Drug: Sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (1 g QID before meals)
Trial: 31639790
Drug: Nicorandil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (10 mg, t.i.d., starting 2 days before and continuing for 2 days after the procedure)
Trial: 31639790
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard hydration treatment only)
Trial: 25111433
Drug: Behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavior therapy (behavior activation and problem-solving therapy)
Trial: 21654719
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (tri-weekly for 6 weeks)
Trial: 15689052
Drug: D‐003 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D‐003 (20 mg/day)
Trial: 8481017
Drug: Ketotifen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (2 to 4 mg per day)
Trial: 3115210
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg four times a day)
Trial: 3891188
Drug: Sulindac (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (200 mg twice a day)
Trial: 23784369
Drug: Umeclidinium (10-350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium (10-350 μg)
Trial: 23784369
Drug: Umeclidinium (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium (100 μg and above)
Trial: 25289942
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide (18 μg)
Trial: 21757893
Drug: Marine omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marine omega-3 fatty acids (2,080 mg daily for 10 weeks)
Trial: 19452380
Drug: Aripiprazole titrated-dose
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole titrated-dose (starting dose 5 mg/day)
Trial: 19452380
Drug: Aripiprazole fixed-dose
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole fixed-dose (dose 15 mg/day)
Trial: 19452380
Drug: Aripiprazole titrated-dose
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole titrated-dose
Trial: 19452380
Drug: Aripiprazole fixed-dose
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole fixed-dose
Trial: 16422995
Drug: Citalopram 20
RxNorm normalized name: citalopram 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram 20 mg i.v.
Trial: 8204472
Drug: Cyclosporin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin (5 mg/kg daily for 6 weeks)
Trial: 3284632
Drug: Marital therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marital therapy designed to enhance intimacy through self-disclosure
Trial: 29184167
Drug: Nebivolol (NEB)
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol (NEB) 5/10 mg/day
Trial: 29184167
Drug: Atenolol (ATE)
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol (ATE) 25/50 mg/day
Trial: 25403327
Drug: Rapeseed/canola oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapeseed/canola oil (RA) supplementation (50 g daily for 4 weeks)
Trial: 25403327
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (OL) supplementation (50 g daily for 4 weeks)
Trial: 22591446
Drug: Motor physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor physical therapy combined with neuromuscular electrical stimulation (NMES) on the tibialis anterior
Trial: 22591446
Drug: Motor physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motor physical therapy alone
Trial: 17559750
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (NIASPAN) 1 g (N1)
Trial: 17559750
Drug: Extended-release niacin
RxNorm normalized name: niacin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release niacin (NIASPAN) 2 g (N2)
Trial: 15252223
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy at a dosage of 80-100 mg per day
Trial: 15252223
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy at a dosage lower than 40 mg per day
Trial: 15252223
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy with treatment duration of 90 days or less
Trial: 886702
Drug: Preventive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive therapy for the 'intermediate' group (350 persons)
Trial: 31451420
Drug: Inactivated varicella
RxNorm normalized name: VARICELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated varicella zoster virus vaccine
Trial: 23547959
Drug: Students unfamiliar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Students unfamiliar with treatment and remedies for WMSD
Trial: 21467701
Drug: Efavirenz with
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Efavirenz with fixed-dose lamivudine and abacavir
Trial: 21467701
Drug: Ritonavir-boosted atazanavir
RxNorm normalized name: atazanavir and ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted atazanavir with fixed-dose lamivudine and abacavir
Trial: 19628136
Drug: Project ALERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Project ALERT (school-based drug prevention program)
Trial: 3804564
Drug: Ephedrine/methylxanthine mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine/methylxanthine mixture (22 mg ephedrine, 30 mg caffeine, 50 mg theophylline)
Trial: 25072937
Drug: Nω‐hydroxy‐nor‐L‐arginine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nω‐hydroxy‐nor‐L‐arginine (0.1 mg/min)
Trial: 22594233
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser irradiation after root canal therapy and conservative periodontal treatment
Trial: 22594233
Drug: Root canal
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root canal therapy and conservative periodontal treatment (scaling and root planning)